Camilla L Marvig1, Talitha I Verhoef2, Anthonius de Boer2, Farhad Kamali3, Ken Redekop4, Munir Pirmohamed5, Ann K Daly3, Vangelis G Manolopoulos6, Mia Wadelius7, Marcel Bouvy2, Anke H Maitland-van der Zee8. 1. Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 2. The Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht. 3. Institute of Cellular Medicine, Newcastle University Medical School, Framlington Place, NE2 4HH, Newcastle upon Tyne, United Kingdom. 4. Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands. 5. The Wolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom. 6. Laboratory of Pharmacology, Democritus University of Thrace Medical School, Alexandroupolis, Greece. 7. Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden. 8. The Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht. Electronic address: a.h.maitland@uu.nl.
Abstract
INTRODUCTION: Little is known about the overall quality of life (QOL) in patients newly diagnosed with venous thromboembolism (VTE) and atrial fibrillation (AF). We studied QOL in patients with VTE and AF immediately after the start of anticoagulant therapy, and after three months of treatment. Furthermore we identified whether QOL was affected by age, gender and nationality. MATERIALS AND METHODS: The European pharmacogenetics of anticoagulant therapy (EU-PACT) study was a multicentre, randomized controlled trial of patients aged >18years diagnosed with VTE or AF. QOL was assessed using EuroQol 5 dimensions (EQ-5D) questionnaires. RESULTS: The EQ-5D questionnaires were completed by 187 patients with VTE and 660 patients with AF. The QOL in patients diagnosed with VTE or AF was significantly impaired, however, during a 3months treatment period, patients experienced an improvement (p<0.05). The QOL in patients diagnosed with VTE improved with increasing age, with similar effects seen in men and women. Men and women diagnosed with AF differed in QOL (respectively 0.84 and 0.74, p<0.05), and QOL decreased with age. Comparison between countries showed significant differences in the EQ-Index score at follow-up of patients with VTE, and in both EQ-Index score and EQ-VAS of patients with AF. CONCLUSIONS: The QOL in patients with VTE and AF is strongly reduced directly after the start of anticoagulant treatment, but improves within 3months. Moreover, QOL is influenced by demographic and disease-specific variables. These findings provide useful information for future cost-effectiveness studies.
INTRODUCTION: Little is known about the overall quality of life (QOL) in patients newly diagnosed with venous thromboembolism (VTE) and atrial fibrillation (AF). We studied QOL in patients with VTE and AF immediately after the start of anticoagulant therapy, and after three months of treatment. Furthermore we identified whether QOL was affected by age, gender and nationality. MATERIALS AND METHODS: The European pharmacogenetics of anticoagulant therapy (EU-PACT) study was a multicentre, randomized controlled trial of patients aged >18years diagnosed with VTE or AF. QOL was assessed using EuroQol 5 dimensions (EQ-5D) questionnaires. RESULTS: The EQ-5D questionnaires were completed by 187 patients with VTE and 660 patients with AF. The QOL in patients diagnosed with VTE or AF was significantly impaired, however, during a 3months treatment period, patients experienced an improvement (p<0.05). The QOL in patients diagnosed with VTE improved with increasing age, with similar effects seen in men and women. Men and women diagnosed with AF differed in QOL (respectively 0.84 and 0.74, p<0.05), and QOL decreased with age. Comparison between countries showed significant differences in the EQ-Index score at follow-up of patients with VTE, and in both EQ-Index score and EQ-VAS of patients with AF. CONCLUSIONS: The QOL in patients with VTE and AF is strongly reduced directly after the start of anticoagulant treatment, but improves within 3months. Moreover, QOL is influenced by demographic and disease-specific variables. These findings provide useful information for future cost-effectiveness studies.
Authors: Ling-Hsiang Chuang; Pearl Gumbs; Ben van Hout; Giancarlo Agnelli; Sonja Kroep; Manuel Monreal; Rupert Bauersachs; Stephen N Willich; Anselm Gitt; Patrick Mismetti; Alexander Cohen; David Jimenez Journal: Qual Life Res Date: 2019-04-04 Impact factor: 4.147
Authors: Abdullah U Althemery; Abdullah A Alfaifi; Abdulrahman Alturaiki; Maha A L Ammari; Khizra Sultana; Leanne Lai Journal: Ann Thorac Med Date: 2020-04-03 Impact factor: 2.219